Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 27, 2020SANTA BARBARA, Calif., Feb 27, 2020 -- Direct Relief, BD (Becton, Dickinson and Company) and the National Association of Free & Charitable Clinics (NAFC) today announced $125,000 in funding for...
Feb 20, 2020FRANKLIN LAKES, N.J., February 20, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD Synapsys™ microbiology...
Feb 17, 2020BD Kiestra™ ReadA is device listed with the U.S. FDAFRANKLIN LAKES, N.J., February 17, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the BD Kiestra™ ReadA is device...
Feb 13, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new, $6 million contract with the Fleming Fund, a U.K. aid program that helps low-...
-
Feb 12, 2020New capillary blood collection device combined with innovative sample handling and analytical technologies in clinical studies aim to make diagnostic blood testing more accessible and convenient
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term...
-
Feb 11, 2020
FRANKLIN LAKES, N.J. (Feb. 11, 2020) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the completion of a 50-subject human clinical trial with...
Feb 6, 2020- As reported, revenues of $4.225 billion increased 1.6 percent.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.225 billion for the first fiscal quarter ended December 31,...
-
Jan 29, 2020Three-year mortality and amputation data for Lutonix® 014 Drug-Coated Balloon Below-The-Knee IDE trial presented at LINC
FRANKLIN LAKES, N.J. (Jan. 29, 2020) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that interim findings from the Lutonix below-the-knee...
-
Jan 27, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on March 31, 2020 to holders of record on March 10,...
-
Jan 23, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday,...
-
Jan 17, 2020
The meta-analysis published by Dr. Konstantinos Katsanos, et al in the Journal of Vascular and Interventional Radiology on January 14 focused on amputation-free survival (defined as freedom from...
-
Jan 9, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2020 earnings conference call on Thursday, February 6, 2020, at 8:00...
Jan 3, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday,...
Nov 25, 2019The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 cents per common share, an increase of 2.6 percent from the previous quarter....
-
Nov 22, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday,...
Nov 21, 2019New antimicrobial stewardship technology will be demonstrated at ASHP 2019 Midyear MeetingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its latest advancement in combating antimicrobial resistance (AMR) with new analytics...
-
Nov 18, 2019BD Kiestra™ IdentifA system is available in Europe (CE marked) and Canada
FRANKLIN LAKES, NJ (November 18, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) and...
-
Nov 15, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it has been notified of an unsolicited mini-tender offer by TRC Capital Investment Corporation ("TRC") to purchase up to 500,000...
Nov 14, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Jefferies 2019 London Healthcare Conference on Thursday,...
Nov 12, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug...
-
Nov 5, 2019- As reported, full fiscal year revenues of $17.290 billion increased 8.2 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30,...
-
Oct 29, 2019
FRANKLIN LAKES, N.J., and WAGENINGEN, THE NETHERLANDS, October 29, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points...
-
Oct 28, 2019BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit is designed and tested to work with BD Rhapsody™ Single-Cell Analysis System, BD® AbSeq reagents and BD® Single-Cell Multiplexing Kit
Franklin Lakes, N.J., October 28, 2019 – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the availability of BD Rhapsody WTA Amplification kit...
-
Oct 3, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday,...
-
Sep 28, 2019Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug...
Sep 26, 2019Thomas E. Polen Appointed Chief Executive Officer, Effective Jan. 28, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020,...
Aug 21, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Wells...
Aug 6, 2019- As reported, revenues of $4.350 billion increased 1.7 percent.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.350 billion for the third fiscal quarter ended June 30, 2019....
-
Jul 23, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on management of the environmental, social and...
-
Jul 22, 2019
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on September 30, 2019 to holders of record on...
-
Jul 18, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100...
-
Jul 2, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference call on Tuesday, August 6, 2019, at 8:00 a.m....
-
Jun 20, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory...
-
Jun 4, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash, in the...
-
Jun 4, 2019Findings Based on Survey of 650 Health Care Professionals
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in...
-
Jun 3, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority...
-
May 31, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on...
-
May 20, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the...
-
May 9, 2019- As reported, revenues of $4.195 billion decreased 0.6 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.195 billion for the second fiscal quarter ended March 31, 2019....
Apr 30, 2019New BD ChloraPrep™ Skin Preparation is the Only Commercially Available CHG Antiseptic Skin Preparation with Sterile Solution Designation in the U.S.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for BD ChloraPrep™...
Apr 8, 2019BD BACTEC™ Platelet Quality Control Media is cleared by the U.S. Food and Drug Administration and CE-IVD marked for platelet testingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global availability of BD BACTEC™ platelet quality control media, which allows...
Mar 26, 2019BD FACSDuet(TM) system raises the bar on flow cytometry automation offering a fully integrated sample-to-answer solution with the BD FACSLyric(TM) clinical flow cytometerBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVD certification for the BD FACSDuet(TM) automated flow cytometry system. The...
-
Mar 21, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to the recent letter from FDA to health care providers...
Mar 14, 2019Venovo(TM) Venous Stent proven safe and effective in iliac and femoral veinsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo(TM)...
-
Feb 13, 2019BD WavelinQ™ 4F EndoAVF System Receives 510(k) Clearance from U.S. Food and Drug Administration
FRANKLIN LAKES, N.J., February 13, 2019 –BD (Becton, Dickinson and Company), a leading global medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration for...
-
Feb 5, 2019- As reported, revenues of $4.160 billion increased 35.1 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for the first fiscal quarter ended December 31,...
-
Jan 24, 2019BD Nano(TM) Second Generation Pen Needle Receives 510(k) Clearance from U.S. Food and Drug Administration
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the U.S. Food and Drug Administration 510(k) clearance of its second generation BD Nano(TM)...
-
Dec 20, 2018BD MAX(TM) Enteric Viral Panel Receives 510(k) Clearance from U.S. Food and Drug Administration
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of its BD MAX(TM) enteric viral...
Dec 11, 2018BD FACSLyric(TM) Flow Cytometer is First BD Product to Earn UL Cybersecurity Assurance Program CertificationBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL. This...
-
Nov 29, 2018Learn how advanced analytics can help combat a critical component of the opioid epidemic at the #ASHP18 Midyear Meeting
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new software application designed to help hospitals and health systems...